Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 3,000
- 试验地点
- 1
- 主要终点
- Long term cardiovascular mortality
研究概览
简要总结
The objective of this work is to investigate and then to sequence new biomarkers in the plasma of patients presenting with dyspnea secondary or not to heart failure, and study their diagnostic and prognostic value.
详细描述
Plasma samples for patients with dyspnea, edema, with or without heart failure; ambulatory or admitted for cardiac decompensation (even with cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be prospectively collected.
The objective of this work is to investigate and then to sequence new proteins in the plasma of these patients for diagnostic and prognostic purpose.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients presenting with shortness of breath secondary or not to heart failure, even with cardiac shock and LVAD.
- •Patients with valvular disease
- •chronic stable heart failure.
- •post- partum Cardiomyopathy
排除标准
- •terminal cancer
- •progressive neurological disease
- •pregnancy
- •opposition of the patient
结局指标
主要结局
Long term cardiovascular mortality
时间窗: Prospective at 12 months
To detect prognostic values of plasma biomarkers, we assess cardiovascular mortality at 3, 6, and 24 months.
次要结局
- Diagnostic value of new biomarkers.(at day 0)
- Cardiac hospitalization(s) at 3, 6,12 and 24 months(Prospective at 12 months)